Metabolic syndrome may increase risk for liver cancer

Apr 03, 2011

Scientists have confirmed that metabolic syndrome, a constellation of conditions that increases the risk of heart disease and diabetes, may also increase the risk of the two most common types of liver cancer, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

Katherine McGlynn, Ph.D., a senior investigator at the National Cancer Institute, said approximately one-third of the U.S. population has , which is defined as the co-occurrence of at least three of the following five conditions: raised blood pressure, elevated , low HDL or "good" cholesterol, raised triglyceride levels and raised fasting plasma glucose levels.

According to McGlynn, persons with these conditions may be at increased risk of developing hepatocellular and intrahepatic cholangiocarcinoma.

Liver cancer incidence has been rising since the 1980s in the United States. The factors related to the increase are not well understood. "A lot of attention has focused on viral risk factors, but a significant part of the increase may be due to metabolic syndrome, as well as to diabetes and obesity," said McGlynn.

"The prognosis for liver cancer is only marginally better than the prognosis for pancreatic cancer, with a five-year survival of approximately 10 percent," she said. "Prognosis is more favorable, however, when liver cancers are diagnosed at early stages when they are small and localized to the liver."

For the current study, researchers identified 3,649 cases of hepatocellular carcinoma and 743 cases of intrahepatic cholangiocarcinoma. They compared the medical history of these patients with the medical histories of 195,953 cancer-free adults.

Statistical analyses showed that the persons with liver cancer were significantly more likely than cancer-free persons to have a prior history of metabolic syndrome: 37.1 percent of patients with hepatocellular carcinoma had pre-existing metabolic syndrome, as did 29.7 percent of patients with intraheptic carcinoma; only 17.1 percent of the cancer-free adults had metabolic syndrome.

Explore further: AstraZeneca cancer drug, companion test approved

add to favorites email to friend print save as pdf

Related Stories

Metabolic syndrome ups colorectal cancer risk

Oct 06, 2008

In a large U.S. population-based study presented at the 73rd Annual Scientific Meeting of the American College of Gastroenterology, metabolic syndrome patients had a 75 percent higher risk of colorectal cancer compared to ...

Metabolic factors may play a role in risk for breast cancer

Jun 30, 2009

Physiological changes associated with the metabolic syndrome may play a role in the risk of postmenopausal breast cancer, according to study results published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the ...

Personalized treatment may help some liver cancer patients

Oct 22, 2010

A more personalized treatment for people with a type of metastatic liver cancer --hepatocellular carcinoma -- may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers. Hepatocellular ...

Recommended for you

Putting the brakes on cancer

Dec 19, 2014

A study led by the University of Dundee, in collaboration with researchers at our University, has uncovered an important role played by a tumour suppressor gene, helping scientists to better understand how ...

Peanut component linked to cancer spread

Dec 19, 2014

Scientists at the University of Liverpool have found that a component of peanuts could encourage the spread and survival of cancer cells in the body.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.